Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.20.4
Consolidated Statements of Operations - USD ($)
12 Months Ended
Oct. 31, 2020
Oct. 31, 2019
Income Statement [Abstract]    
Revenue $ 250,000
Operating costs and expenses:    
Inventor royalties, contingent legal fees, litigation and licensing expenses 166,250
Amortization of patents 418,750
Research and development expenses (including non-cash share based compensation expenses of $1,484,545 and $2,825,630, respectively) 4,381,205 5,473,427
General and administrative expenses (including non-cash share based compensation expenses of $2,652,915 and $2,888,115, respectively) 5,596,997 5,662,828
Impairment in carrying amount of patent assets (Note 2) 418,750
Total operating costs and expenses 9,978,202 12,140,005
Loss from operations (9,978,202) (11,890,005)
Loss on disposal of property and equipment (148,084)
Interest income 33,923 71,353
Net loss (10,092,363) (11,818,652)
Less: Net loss attributable to noncontrolling interest (74,008) (171,598)
Net loss attributable to common stockholders $ (10,018,355) $ (11,647,054)
Net loss per share: Basic and diluted $ (0.45) $ (.59)
Weighted average common shares outstanding: Basic and diluted 22,229,042 19,789,795